Abbott (ABT) Tops Q4 EPS by 11c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook
January 25, 2023 7:30 AM ESTFourth-quarter sales of $10.1 billion; full-year 2022 sales of $43.7 billionFull-year 2022 sales growth of 1.3 percent; organic sales growth of 6.4 percentFull-year 2022 GAAP diluted EPS of $3.91; adjusted diluted EPS of $5.34Continues to strengthen portfolio with steady cadence of new product approvals
ABBOTT PARK, Ill., Jan. 25, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2022.
Fourth-quarter sales of $10.1 billion, which were negatively impacted by an expected year-over-year decline in COVID-19 testing-related sales, decreased 12.0 percent on a reported basis... More